Bio News
Switzerland-based Roche has entered into a partnership with biotech startup Dualitas Therapeutics to discover bispecific antibodies for immune diseases, paying $36.5 million (approximately 48.9 billion won) upfront.
Dualitas will screen more than 300,000 bispecific antibody combinations and provide Roche with new investigational drug candidates. The company is eligible to receive up to $1 billion in milestone payments, as well as future sales royalties.
Dualitas is developing its own candidate, DTX-102, as a treatment for rheumatoid arthritis and expects to enter clinical development in 2027.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
